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Despite the launch of a new national contraceptive policy in 
2012 and the introduction of the implant contraceptive in 2014,[1] 
South Africa (SA) is making slow progress in reducing levels of 
unintended pregnancies, including among teenagers.[2] Implants 
and the intrauterine device (IUD), both referred to as long-acting 
reversible contraceptives (LARCs), have much greater effectiveness 
than short-acting alternatives.[3,4] Oral contraceptives, for example, 
have contraceptive failure rates as high as 20/100 woman-years[5] 
compared with a failure rate of 0.05% for the implant and 0.8% for 
the copper IUD.[4] Given the ‘unmatched effectiveness’[6] of implants 
and continuation rates of ~80% at 1 year in multiple assessments 
globally,[4,7,8] some proponents consider implants – alongside IUDs 
– to be ‘first-line’ contraceptives, and other methods as ‘second-tier’.[9] 
Indeed, professional bodies in the USA recommend that providers must 
emphasise that LARCs are ‘the best reversible methods for preventing 
unintended pregnancy, rapid repeat pregnancy, and abortion in 
young women’.[10,11] In SA, Implanon is currently used to provide 
pregnancy protection for 3 years, but increasingly evidence suggests 
that protection may extend to 5 years, even in women with a high 
body mass index.[12,13] Prolonged effectiveness would further improve 
Implanon’s convenience for women, and reduce removal procedures 
and costs of implant replacements. 
Despite the effectiveness and programmatic advantages of the 
implant, its promise has not been realised in SA. The number of 
implants inserted in the public sector has fallen from ~175 000 in 
2014/2015 to only 50 000 in 2016/2017,[14] with declines noted in all 
provinces of the country (Fig. 1). Levels of uptake have been especially 
low in Mpumalanga, the Northern Cape and North West Province 
since the introduction of the implant. Similar concerns prevail around 
the copper IUD, which accounts for only 2% of all contraceptive use, 
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Progress in reducing unintended pregnancies in South Africa is slow. The implant, introduced in 2014, expanded the range of available long-
acting reversible contraceptives (LARCs) and held much promise. Uptake, however, has declined precipitously, in spite of its ‘unmatched 
effectiveness’ and high levels of satisfaction for most users. We propose policy and provider interventions to raise implant use, underscored 
by a ‘LARC-first’ approach. Contraceptive counselling should focus on the particular benefits of LARCs and methods be presented in order 
of effectiveness. Moreover, implants hold particular advantages for certain groups, especially adolescents and young women, in whom it 
is considered first-line contraception. Provision of immediate postpartum and post-abortion implants is safe and highly acceptable, yet 
remains under-utilised. Implant services at HIV and tuberculosis clinics are a key priority, as is inclusion of LARC provision within school 
health services. Implants could also be delivered by existing mobile outreach services, for example in sex worker programmes. Services 
could be built around nurses dedicated solely to providing implants, with other health workers receiving brief refresher training. Women 
who experience side-effects, especially abnormal bleeding, require timely interventions, following a standardised protocol, including use of 
medications. Encouraging return for side-effects, follow-up phone calls and home visits would raise continuation rates. Removal services 
require doctor support or designated nurses at specific centres. Limited access to removal services, health workers’ resistance or botched 
procedures will further undermine implant provision. Rapid implant demonstration projects in postpartum wards, schools, outreach 
services and by dedicated providers may rapidly advance the field. Together, the actions outlined here will ensure that the implant fulfils its 
potential and reinvigorates family planning services. 
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Fig. 1. Total numbers of implant insertions for each province in South Africa 
from April 2014 to March 2017[14] (no data are available for the Eastern 
Cape, the Free State, North West, or the Western Cape for financial year 
2015). (FY = financial year.)
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mainly because of limited nurse training in insertion and suboptimal 
access in family planning clinics.[15] In addition, the longstanding 
question of whether depot medroxyprogesterone acetate (DMPA) 
increases women’s risk for HIV acquisition will soon be answered by 
the Evidence for Contraceptive Options and HIV Outcomes (ECHO) 
study.[16] If a significant association is demonstrated, there may be a 
compelling reason to restrict the provision of injectables for women 
at high risk of HIV infection. 
Against this background, SA needs to redouble its efforts to 
improve contraceptive access for all women, especially to LARCs. 
This commentary therefore proposes a new approach for SA, 
described by Hathaway et al.,[17] centring on the concept of ‘Any 
woman, any place, any time’, which holds that women should have 
access to LARCs in a range of complementary settings. We outline 
the policy, systems and provider interventions required to support 
this approach (Table 1).[18]
Building the workforce for implant 
provision
A range of health worker cadres are required, including staff 
dedicated solely to LARC provision. In Zambia, retired midwives 
were placed at high-volume, public-sector facilities solely to provide 
LARCs. Only 18 of these facilities were able to insert >22 000 implants 
in 14 months, which is nearly half of the number inserted in all of 
SA in 2016/2017.[19] As dedicated providers have the necessary time 
and skills – and a mandate – they were able to generate demand, 
provide quality services and guide the work of other family planning 
staff.[19] Dedicated providers cannot function in isolation and require 
tightly ring-fenced time, sufficient clients, supplies and supervision 
to allow them to maintain competency, confidence and produc t i-
vity.[20] In many parts of sub-Saharan Africa, dedicated providers 
also deliver implant services through mobile outreaches, which can 
rapidly increase implant uptake.[8,21] Existing outreach services in 
SA, for example to schools and among groups such as female sex 
workers,[22] provide a solid platform for such services. Projects pilot-
ing provision of implants in outreach services and through dedicated 
providers are needed. 
While implant provision is built around nurses, doctors need to 
play a larger role, especially regarding removal procedures. Further-
more, in several settings in Africa and Asia, LARC services rely 
heavily on community health workers (CHWs).[23-25] They lead 
community-based distribution of the implant, visit users’ homes 
and provide support for women experiencing side-effects. A study 
in rural Northern Nigeria, where CHWs were tasked with inserting 
implants, showed the importance of frequent supervisory visits 
for CHWs.[24] In the absence of such support, CHWs reverted to 
dispensing shorter-acting methods.[26] CHWs in SA, especially at 
‘primary healthcare re-engineering’ sites,[27] and HIV lay counsellors 
– already adept at ‘task shifting’ – could play an important role in 
implant services through demand creation, conducting pre-insertion 
counselling around LARCs and providing follow-up support. 
Brief, carefully designed training can raise uptake and con-
tinuation of the implant. A cluster-randomised trial involving 
40 clinics in the USA demonstrated the effectiveness of a half-day 
training intervention of healthcare workers. Following the training, 
twice as many women chose a LARC method and subsequent rates 
of unintended pregnancy were cut by 50% compared with controls.[28] 
Training in this and other instances have included orientation to tools 
such as procedural checklists, contraceptive effectiveness charts, 
clinical case discussions, practical training with anatomical models 
and audiovisual materials.[29] To be effective, however, training does 
need to be carefully planned and accompanied by other interven-
tions to strengthen service delivery. In a study in Bangladesh, for 
example, training was largely ineffective, as health system weaknesses 
constrained the potential for service improvements.[30] SA data also 
indicate that training that is too short and does not include manage-
ment of side-effects and removals, may be inadequate to support 
implant provision.[31,32] 
Pre-insertion counselling and ongoing 
support
Adopt a ‘LARC first’ structured approach to contraceptive counsel-
ling. The content of contraceptive counselling heavily influences 
method selection, especially among younger women.[33-35] While it 
is important to avoid coercion and ensure patient-centred, shared 
decision-making, we contend that it is time for a more directive 
approach, one in which women are explicitly informed that LARCs 
constitute first-line contraception. In this approach, counselling 
is standardised and methods are presented in order from most to 
least effective.[36] Currently, it appears that during family planning 
counselling in SA, little attention is given to the relative effectiveness 
of different contraceptives, even though these can vary by as much as 
100-fold.[4,32] Existing social media platforms, especially MomConnect 
and NurseConnect, have a key role to play in propagating messaging 
Table 1. ‘Any woman, any place, any time’ approach: Addressing the patient, system and provider barriers to implant initiation and 
continuation
Target population groups Settings for implant provision Health workers
Women attending family planning clinic, including first-
time users, women unsure about method, and women 
seeking renewal of short-acting method
Family planning clinics and primary healthcare 
clinics
Primary care nurses, dedicated 
LARC providers, and  
doctors (removals)
Adolescents and young women Schools, youth-friendly services,  campus clinics 
and technical colleges
School health nurses, 
dedicated LARC providers
Postpartum women Labour wards (demand generated in ante- 
natal clinics)
Midwives (labour wards and 
antenatal clinics)
Post-abortion women Termination-of-pregnancy  wards Nurses
Special target populations, such as HIV-infected women, 
TB patients, sex workers
Mobile outreaches
HIV and TB clinics
Dedicated LARC providers, 
CHWs, and HIV lay 
counsellors
Communities Community settings, households CHWs, and HIV lay 
counsellors
LARC = long-acting reversible contraceptive; CHW = community health worker; TB = tuberculosis.
941       November 2017, Vol. 107, No. 11
CME
around ‘LARCs first’ and generating demand 
for these methods. Strategies targeting men 
are also required. 
‘Anticipatory guidance’ before implant 
insertion can prepare women for side-
effects.[18] The key topic to discuss before 
implant insertion is potential bleeding 
changes and the acceptability to the client 
within her sociocultural and relationship 
context. This is important, as changes in 
uterine bleeding patterns, while generally 
not harmful, are to be expected with 
implant use. Even though rates vary across 
studies, generally, of 100 women who use 
Implanon, ~30 will have no bleeding at 
all or no change to their normal bleeding 
patterns, 30 will have lighter, less frequent 
bleeding than usual, 15 - 20 will report 
prolonged, heavy nuisance bleeding, and 5 - 15 
will experience intolerable bleeding resulting 
in implant removal (Fig. 2).[37-39] Jadelle and 
a similar device, the Sino-implant, have 
fewer bleeding side-effects than Impla-
non.[13,37,40,41] Continuation rates were also 
better with Jadelle than Implanon in several 
studies,[37,41] but not in a multi-country 
randomised trial.[40]
Women should be given written informa-
tion, providing further explanation of 
changes in bleeding patterns that could be 
antici pated and the possibilities of treatment 
for these.[42] While anticipatory guidance is 
likely to be useful, it is clearly difficult 
to fully prepare women for the reality of 
heavy or prolonged bleeding. Such bleeding 
patterns have substantial deleterious effects 
on a woman’s comfort, on costs of sanitary 
protection and on sexual relations. In a 
study of SA women, considerably more 
married or cohabiting women removed 
the implant owing to bleeding side-effects 
than those who were single or in casual 
relationships, suggesting that implants may 
be especially suited to the latter groups.[32] It 
is important, however, to consider the effects 
of the implant on overall sexual health, as 
most women do not experience increased 
bleeding and the certainty of highly effective 
contraception may, in fact, increase sexual 
pleasure. A study in the USA showed that 
35% of implant users reported an improved 
sex life, 48% reported no change and 17% 
reported a worsened sex life.[4,3] 
Actively follow-up implant users and 
strongly encourage them to return to the 
clinic for advice, reassurance, treatment of 
side-effects or implant removal, if desired.
Women seldom return to the clinic to 
discuss problems encountered with the 
implant; instead, they rely on friends, the 
internet and social media to help them to 
decide whether to remove the implant.[44] 
Social media contain many useful, accurate 
resources, presenting the implant from a 
patient’s perspective, although admittedly 
alongside much misinformation.[45] In a trial 
in India, actively following up implant users 
through phone calls or home visits was able 
to raise continuation rates.[46] Calls, lasting 
4 minutes on average, might be feasible 
in SA, given that women’s contact details 
are routinely collected at each clinic visit, 
although these details are often incomplete 
and subject to frequent changes.[47] Other 
studies examining active follow up had less 
promising findings, even though these were 
mostly in high-income countries and had 
weaker study designs.[48-50]
Intervene as soon as possible when 
bleed ing is presented as a problem. Often, 
when women do return to the clinic for 
advice about side-effects, they are simply 
told to ‘persevere’ or ‘wait and see’;[44,51] yet, 
these encounters are critical, as they may be 
the final chance for supporting continuation 
of the method. The large majority of patients 
who present with problems subsequently 
remove the device. Supportive interventions 
at such visits appear to be especially effective 
at raising continuation among adolescents 
and young women.[52] Health workers 
require a protocol for managing abnormal 
bleeding, which encompasses the routine 
use of appropriate medications, including 
long-term therapies. Medications can 
include non-steroidal anti-inflammatory 
drugs, such as ibuprofen and mefenamic 
acid, and hormonal drugs, such as combined 
oral contraceptives or ethinyl oestradiol.[53] 
Although health workers in SA commonly 
prescribe treatment for bleeding and 
headaches related to the implant, medi-
cation regimens vary considerably and a 
standardised approach is needed.[31,32]
Health workers’ resistance to removals, or 
other failures in accessing removal services, 
will rapidly tarnish the implant’s image 
and potentially undermine the entire fam-
ily planning programme. Service delivery 
capacity for removals is a problem in many 
places[54] and women often resort to pri-
vate sector providers.[32] Opportunities for 
nurses to become skilled in implant removals 
were limited in the early years after implant 
introduction when demand for removals was 
low. In SA, this resulted in a number of 
botched removals or repeated unsuccessful 
attempts at removal, fuelling negative media 
and community coverage for the implant.[55] 
Selected family planning nurses and doctors 
must be trained to perform removals and be 
counselled that they only encounter women 
with side-effects, which may give them a false-
ly nega tive impression of the method. The 
majority of women find the method highly 
satisfactory and therefore don’t interface with 
the system until time of removal. In cases of 
difficult removals, either anticipated or after a 
single failed attempt at removal, nurses must 
immediately refer for expert support, rather 
than persisting in their efforts.
Targeting of population 
groups
Although suitable for ‘any woman’, the 
implant has been most successfully targe-
ted at specific populations, most especially 
youth, first-time contraceptive users, and 
postpartum and post-abortion women. 
Making implants and other LARCS acces-
sible for these groups must be considered 
a major priority for family planning in SA, 
signalling a step change for the national pro-
gramme. Conducting a few rapid demon-
stration projects may provide the impetus 
needed for widespread implementation. 
LARCs should be first-line contra -
ceptive options for adolescents and young 
women. Counselling focused on the parti-
cular effi cacy and benefits of LARCs is able 
to lower the rates of pregnancy and abortion 
in adolescents and young women.[56] In one 
large study, two-thirds of youth were still 
using a LARC after 2 years, compared with 
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Fig. 2. Approximate continuation rates and likelihood of bleeding and headache side-effects. Rates of 
side-effects and of continuation vary between studies; the figures provided are indicative.
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only one-third of those who had selected a non-LARC method. In 
most studies, rates of implant continuation in young women were 
higher than in older women (Fig. 2).[7,57] 
In Kenya, when implants were made available to young women 
seeking family planning, a quarter selected the method.[58] In SA, 
such advances may be hampered by healthcare providers’ opinions, 
which are often divergent from laws governing contraceptive access 
among adolescents.[59] Value judgements about sexual activity among 
youth may even lead to girls being denied contraceptives. The 
ongoing refusal to provide contraceptives in schools in the face of 
rising pregnancy rates among learners, can no longer be justified 
from a public health and gender equity perspective, and is at odds 
with World Health Organization guidance on safeguarding human 
rights in the provision of contraceptive services for young women.[60] 
A national policy recommending LARCs as first-line contraception 
and in-school provision of these services, either through provision by 
visiting nurses or mobile clinics, would go a long way to overcoming 
these access barriers.
Postpartum and post-abortion family planning services 
represent a critical pregnancy prevention tool that remains surpri-
singly under-utilised. Short inter-pregnancy intervals are associated 
with negative maternal and infant health outcomes, and an interval 
of at least 2 years between pregnancies is recommended.[61] More 
than 10 trials, including one in sub-Saharan Africa,[62] have examined 
the safety, uptake and continuation rates of implant provision in the 
immediate postpartum period.[63] Implants inserted within 48 hours 
postpartum appear not to affect lactation, growth, and neonatal and 
infant development.[64-66] In a trial in the USA,[66] as many as 90% of 
adolescents took up the offer of an implant after delivery, and uptake 
rates were also high in Uganda[62] and Kenya.[67] 
For postpartum LARC services to be successful, however, robust 
linkages are required between providers working in family planning, 
antenatal and labour wards. Counselling about postpartum LARC 
placement needs to begin during antenatal care. Attention is required 
to ensure that linkages between family planning providers and 
labour wards are robust enough to avoid undue delays in implant 
insertion, noting that many women are discharged within 24 hours of 
childbirth. If services are not streamlined, women may be instructed 
to return for implant insertion at their 6-week postpartum visit, 
which for many may mean that insertion will not occur.[63] 
Most patients who have had an abortion wish to avoid a subsequent 
pregnancy and strongly desire a post-abortion contraceptive method.[68] 
LARC use among these women appears more effective than short-acting 
contraception in reducing repeat pregnancies and abortions.[69,70] 
In a multi-country trial, insertion of the implant immediately post 
abortion led to higher LARC use and reduced repeat pregnancies 
compared with insertion at a planned follow-up visit.[71] Also, in 
a study in Ethiopia, implant insertion immediately post abortion 
resulted in >80% of women leaving the facility with a contraceptive 
method compared with 58% before the services began.[72] LARC use 
rose from 2% to 55%. 
Provision of the implant at HIV and tuberculosis clinics, 
including for women taking efavirenz, is a key priority. Current 
approaches to family planning service provision in HIV treatment 
programmes have had limited success in reducing unintended preg-
nancies among HIV-infected women. Women receiving antiretroviral 
treatment have frequent contact with health services, providing seve-
ral opportunities for contraceptive provision. Reducing unintended 
pregnancies in these women would offer them considerable benefits, 
but also assist in reducing the number of HIV-infected children. In 
one study, however, in rural Mpumalanga, only a quarter of HIV-
infected women had discussed family planning with their providers.[73] 
There are substantial drug interactions between efavirenz and 
Implanon, considerably reducing drug levels of etonogestrel, the 
active drug in Implanon.[74-76] Interactions between efavirenz and 
Jadelle appear even more pronounced than with Implanon.[77,78] 
Women using an implant, who are also taking efavirenz, have higher 
pregnancy rates than those taking other antiretrovirals. The higher 
adherence to the implant, however, when compared with short-
acting methods including injectable progestins,[79,80] means that 
despite this drug interaction, the implant remains highly effective in 
these women – more so than short-acting alternatives. Available data 
therefore do not support limiting access to the implant in women taking 
efavirenz.[75] Moreover, the use of efavirenz is likely to be phased out 
over time, alleviating many of these concerns. 
Conclusions
The long-standing approach of prioritising contraceptive provision 
through family planning clinics may well account for the slow progress 
made in reducing unintended pregnancies in SA, including among 
adolescent girls. Making LARCs available in postpartum and post-
abortion wards, schools, and HIV and tuberculosis clinics, may help 
make considerable headway. At each contact with the health system, 
women of reproductive age should be asked about their fertility 
intentions and linked with LARC and other contraceptive services, 
as required. LARCs should be considered as first-line contraception 
for adolescents, young women and first-time contraceptive users; 
these groups should be actively targeted in schools and other services. 
The method may also be especially suitable for women in casual 
relationships or those who are single. Also, we recommend that 
demonstration projects be established, where nurses are recruited to 
work solely to provide LARCs and support implant provision more 
generally, especially in clinical outreach services. With additional 
training, existing lay healthcare workers could serve as advocates 
for LARCs and support their ongoing use once selected. Given 
the varying side-effects profile of implant devices, alternatives to 
Implanon might be considered, such as the Sino-implant. 
The clinical management of implant users needs to be improved 
and women should be actively followed up and encouraged to 
return, should bleeding patterns or other side-effects become a 
problem. When a woman does seek advice, the opportunity must be 
capitalised upon to allow early medical management and/or implant 
removal, hence ensuring her ongoing confidence in services and 
in the use of the implant. Women who have difficulties accessing 
removal services or encounter health worker resistance to removal 
may understandably become resentful, stoking rumours and distrust 
in the method and in family planning services more generally.[54] 
Responsive, quality removal services are required, performed by the 
appropriate level of health worker, with supportive expert referral 
when required. Even though the contraceptive efficacy of the 
implant is reduced in women taking efavirenz, the implant may still 
be more effective than alternative methods, and access to implants 
should not be restricted for women taking efavirenz, provided 
adequate counselling is offered. Together, the set of concerted 
actions outlined in this article could ensure that the implant fulfils 
its potential contribution to reducing unintended pregnancies in 
SA. 
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